Britannia Life Sciences Inc. BLAB
CNSX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -21.46% | 98.72% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -21.46% | 98.72% | |||
| Cost of Revenue | -37.02% | 345.50% | |||
| Gross Profit | 1,850.00% | -103.10% | |||
| SG&A Expenses | 261,500.00% | -99.97% | |||
| Depreciation & Amortization | 0.00% | 0.88% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 214.79% | -66.96% | |||
| Operating Income | -2,004.88% | 95.48% | |||
| Income Before Tax | -45.32% | -82.36% | |||
| Income Tax Expenses | -- | -170.80% | |||
| Earnings from Continuing Operations | -64.42% | -68.70% | |||
| Earnings from Discontinued Operations | -- | -77.39% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -67.24% | -69.62% | |||
| EBIT | -2,004.88% | 95.48% | |||
| EBITDA | -27,400.00% | 99.66% | |||
| EPS Basic | -67.48% | -69.59% | |||
| Normalized Basic EPS | -66.67% | 400.00% | |||
| EPS Diluted | -67.48% | -69.59% | |||
| Normalized Diluted EPS | -66.67% | 400.00% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||